Investigational New Drugs 2020-Jul
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
Ο σύνδεσμος αποθηκεύεται στο πρόχειρο
Λέξεις-κλειδιά
Αφηρημένη
Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Keywords: Allergic acute tubulointerstitial nephritis; Medullary thyroid carcinoma; Tyrosine kinase inhibitor; Vandetanib.
